Cytoreductive surgery for metastatic testis cancer

Tissue analysis of retroperitoneal masses after chemotherapy

J. P. Donohue, L. M. Roth, J. M. Zachary, R. G. Rowland, Lawrence Einhorn, S. G. Williams

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Survival of patients with massive retroperitoneal metastases from nonseminomatous germinal cell testis cancer has been enhanced dramatically by preoperative chemotherapy, consisting of platinum, vinblastine and bleomycin. Such chemical, systemic cytoreduction greatly reduces tumor bulk and facilitates retroperitoneal lymph node dessection. However, there are no reliable preoperative or intraoperative predictive criteria to indicate the precise nature of this residual tissue. Even gross morphologic examination is unreliable in ascertaining the presence or absence of persistent cancer in these tissues, which may assume a variety of gross appearances (cystic, solid, necrotic, fibrous and so forth). Retroperitoneal lymph node dissection was done in 51 patients with advanced retroperitoneal disease and/or pulmonary metastases for removal of persistent retroperitoneal mass lesions after 3 or 4 courses of platinum, vinblastine and bleomycin therapy. These patients were analyzed for gross and microscopic features of hemorrhage, inflammation, calcification, fibrosis, necrosis, cystic changes, immature teratoma, mature teratoma and frank cancer (embryonal carcinoma, teratocarcinoma, choriocarcinoma and seminoma). All patients had a combination of several of these features in widely varying gross and regional distributions. Nineteen patients (37 per cent) had some focus of persistent malignancy, often small and seemingly distributed at random in a variety of gross presentations. Furthermore, the site of malignancy often was not in the central largest mass, which usually had necrotic or cystic features. We conclude that mere gross examination and biopsy or removal of the central portion of a residual tumor is inadequate if persistent cancer is to be ruled out. Rather, as complete a dissection as possible is recommended for this purpose. Detailed analysis of gross and microscopic findings will be presented and correlated with clinical management.

Original languageEnglish (US)
Pages (from-to)1111-1114
Number of pages4
JournalJournal of Urology
Volume127
Issue number6
StatePublished - 1982
Externally publishedYes

Fingerprint

Testicular Neoplasms
Drug Therapy
Neoplasms
Vinblastine
Teratoma
Bleomycin
Platinum
Embryonal Carcinoma
Neoplasm Metastasis
Teratocarcinoma
Seminoma
Choriocarcinoma
Residual Neoplasm
Lymph Node Excision
Cystic Fibrosis
Lung Diseases
Dissection
Necrosis
Lymph Nodes
Hemorrhage

ASJC Scopus subject areas

  • Urology

Cite this

Donohue, J. P., Roth, L. M., Zachary, J. M., Rowland, R. G., Einhorn, L., & Williams, S. G. (1982). Cytoreductive surgery for metastatic testis cancer: Tissue analysis of retroperitoneal masses after chemotherapy. Journal of Urology, 127(6), 1111-1114.

Cytoreductive surgery for metastatic testis cancer : Tissue analysis of retroperitoneal masses after chemotherapy. / Donohue, J. P.; Roth, L. M.; Zachary, J. M.; Rowland, R. G.; Einhorn, Lawrence; Williams, S. G.

In: Journal of Urology, Vol. 127, No. 6, 1982, p. 1111-1114.

Research output: Contribution to journalArticle

Donohue, JP, Roth, LM, Zachary, JM, Rowland, RG, Einhorn, L & Williams, SG 1982, 'Cytoreductive surgery for metastatic testis cancer: Tissue analysis of retroperitoneal masses after chemotherapy', Journal of Urology, vol. 127, no. 6, pp. 1111-1114.
Donohue, J. P. ; Roth, L. M. ; Zachary, J. M. ; Rowland, R. G. ; Einhorn, Lawrence ; Williams, S. G. / Cytoreductive surgery for metastatic testis cancer : Tissue analysis of retroperitoneal masses after chemotherapy. In: Journal of Urology. 1982 ; Vol. 127, No. 6. pp. 1111-1114.
@article{a6e7069934ab4e0fa39b075856ed6633,
title = "Cytoreductive surgery for metastatic testis cancer: Tissue analysis of retroperitoneal masses after chemotherapy",
abstract = "Survival of patients with massive retroperitoneal metastases from nonseminomatous germinal cell testis cancer has been enhanced dramatically by preoperative chemotherapy, consisting of platinum, vinblastine and bleomycin. Such chemical, systemic cytoreduction greatly reduces tumor bulk and facilitates retroperitoneal lymph node dessection. However, there are no reliable preoperative or intraoperative predictive criteria to indicate the precise nature of this residual tissue. Even gross morphologic examination is unreliable in ascertaining the presence or absence of persistent cancer in these tissues, which may assume a variety of gross appearances (cystic, solid, necrotic, fibrous and so forth). Retroperitoneal lymph node dissection was done in 51 patients with advanced retroperitoneal disease and/or pulmonary metastases for removal of persistent retroperitoneal mass lesions after 3 or 4 courses of platinum, vinblastine and bleomycin therapy. These patients were analyzed for gross and microscopic features of hemorrhage, inflammation, calcification, fibrosis, necrosis, cystic changes, immature teratoma, mature teratoma and frank cancer (embryonal carcinoma, teratocarcinoma, choriocarcinoma and seminoma). All patients had a combination of several of these features in widely varying gross and regional distributions. Nineteen patients (37 per cent) had some focus of persistent malignancy, often small and seemingly distributed at random in a variety of gross presentations. Furthermore, the site of malignancy often was not in the central largest mass, which usually had necrotic or cystic features. We conclude that mere gross examination and biopsy or removal of the central portion of a residual tumor is inadequate if persistent cancer is to be ruled out. Rather, as complete a dissection as possible is recommended for this purpose. Detailed analysis of gross and microscopic findings will be presented and correlated with clinical management.",
author = "Donohue, {J. P.} and Roth, {L. M.} and Zachary, {J. M.} and Rowland, {R. G.} and Lawrence Einhorn and Williams, {S. G.}",
year = "1982",
language = "English (US)",
volume = "127",
pages = "1111--1114",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Cytoreductive surgery for metastatic testis cancer

T2 - Tissue analysis of retroperitoneal masses after chemotherapy

AU - Donohue, J. P.

AU - Roth, L. M.

AU - Zachary, J. M.

AU - Rowland, R. G.

AU - Einhorn, Lawrence

AU - Williams, S. G.

PY - 1982

Y1 - 1982

N2 - Survival of patients with massive retroperitoneal metastases from nonseminomatous germinal cell testis cancer has been enhanced dramatically by preoperative chemotherapy, consisting of platinum, vinblastine and bleomycin. Such chemical, systemic cytoreduction greatly reduces tumor bulk and facilitates retroperitoneal lymph node dessection. However, there are no reliable preoperative or intraoperative predictive criteria to indicate the precise nature of this residual tissue. Even gross morphologic examination is unreliable in ascertaining the presence or absence of persistent cancer in these tissues, which may assume a variety of gross appearances (cystic, solid, necrotic, fibrous and so forth). Retroperitoneal lymph node dissection was done in 51 patients with advanced retroperitoneal disease and/or pulmonary metastases for removal of persistent retroperitoneal mass lesions after 3 or 4 courses of platinum, vinblastine and bleomycin therapy. These patients were analyzed for gross and microscopic features of hemorrhage, inflammation, calcification, fibrosis, necrosis, cystic changes, immature teratoma, mature teratoma and frank cancer (embryonal carcinoma, teratocarcinoma, choriocarcinoma and seminoma). All patients had a combination of several of these features in widely varying gross and regional distributions. Nineteen patients (37 per cent) had some focus of persistent malignancy, often small and seemingly distributed at random in a variety of gross presentations. Furthermore, the site of malignancy often was not in the central largest mass, which usually had necrotic or cystic features. We conclude that mere gross examination and biopsy or removal of the central portion of a residual tumor is inadequate if persistent cancer is to be ruled out. Rather, as complete a dissection as possible is recommended for this purpose. Detailed analysis of gross and microscopic findings will be presented and correlated with clinical management.

AB - Survival of patients with massive retroperitoneal metastases from nonseminomatous germinal cell testis cancer has been enhanced dramatically by preoperative chemotherapy, consisting of platinum, vinblastine and bleomycin. Such chemical, systemic cytoreduction greatly reduces tumor bulk and facilitates retroperitoneal lymph node dessection. However, there are no reliable preoperative or intraoperative predictive criteria to indicate the precise nature of this residual tissue. Even gross morphologic examination is unreliable in ascertaining the presence or absence of persistent cancer in these tissues, which may assume a variety of gross appearances (cystic, solid, necrotic, fibrous and so forth). Retroperitoneal lymph node dissection was done in 51 patients with advanced retroperitoneal disease and/or pulmonary metastases for removal of persistent retroperitoneal mass lesions after 3 or 4 courses of platinum, vinblastine and bleomycin therapy. These patients were analyzed for gross and microscopic features of hemorrhage, inflammation, calcification, fibrosis, necrosis, cystic changes, immature teratoma, mature teratoma and frank cancer (embryonal carcinoma, teratocarcinoma, choriocarcinoma and seminoma). All patients had a combination of several of these features in widely varying gross and regional distributions. Nineteen patients (37 per cent) had some focus of persistent malignancy, often small and seemingly distributed at random in a variety of gross presentations. Furthermore, the site of malignancy often was not in the central largest mass, which usually had necrotic or cystic features. We conclude that mere gross examination and biopsy or removal of the central portion of a residual tumor is inadequate if persistent cancer is to be ruled out. Rather, as complete a dissection as possible is recommended for this purpose. Detailed analysis of gross and microscopic findings will be presented and correlated with clinical management.

UR - http://www.scopus.com/inward/record.url?scp=0019983001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019983001&partnerID=8YFLogxK

M3 - Article

VL - 127

SP - 1111

EP - 1114

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 6

ER -